Reata Pharmaceuticals Inc
NASDAQ:RETA
Reata Pharmaceuticals Inc
Gross Profit
Reata Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Reata Pharmaceuticals Inc
NASDAQ:RETA
|
Gross Profit
$21.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Reata Pharmaceuticals Inc's Gross Profit?
Gross Profit
21.9m
USD
Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Gross Profit amounts to 21.9m USD.